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The hepatitis C virus encodes a single polyprotein that is pro-
cessed byhost and viral proteases to yield at least 10mature viral
proteins. The nonstructural (NS) protein 5A is a phosphopro-
tein, and experimental data indicate that the phosphorylation
state of NS5A is important for the outcome of viral RNA repli-
cation. We were able to identify kinase inhibitors that specifi-
cally inhibit the formation of the hyperphosphorylated form of
NS5A (p58) in cells. These kinase inhibitorswere used for inhib-
itor affinity chromatography in order to identify the cellular tar-
gets of these compounds. The kinases casein kinase I (CKI), p38
MAPK, CIT (Citron Rho-interacting kinase), GAK, JNK2, PKA,
RSK1/2, and RIPK2 were identified in the high affinity binding
fractions of twoNS5A hyperphosphorylation inhibitors (NS5A-
p58-i). Even though these kinases are targets of theNS5A-p58-i,
the only kinase showing an effect on NS5A hyperphosphoryla-
tion was confirmed to be CKI-. Although this finding does not
exclude the possibility that other kinase(s) might be involved in
basal or regulatory phosphorylation of NS5A, we show here that
NS5A is a direct substrate of CKI-. Moreover, in vitro phos-
phorylation of NS5A by CKI- resulted for the first time in the
production of basal and hyperphosphorylated forms resembling
those produced in cells. In vitro kinase reactions performedwith
NS5A peptides show that Ser-2204 is a preferred substrate res-
idue for CKI- after pre-phosphorylation of Ser-2201.
The hepatitis C virus (HCV)3 is a member of the Flaviviridae
family of single-stranded, positive sense RNA viruses and the
major cause of chronic hepatitis, liver cirrhosis, and hepatocel-
lular carcinoma worldwide. Intensive studies since the discov-
ery of the virus in 1989 have improved therapeutic options, but
they are still inadequate for the majority of patients.
The 9.6-kb RNA genome of HCV is translated into a single
polyprotein, which is then co- and post-translationally processed
by host and viral proteases to yield at least 10mature viral proteins
(C-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B) (1).
We focused our interest on the nonstructural protein NS5A.
NS5A, together with all other nonstructural proteins, is associ-
atedwithmembranous structures thought to be the scaffold for
the formation of the viral replication complex (2, 3). However,
although NS2, NS3/4A, NS4B, and NS5B are tightly associated
with membranes because of the presence of membrane-an-
choring or transmembrane domains (4), NS5A associates with
the endoplasmic reticulum by an amphipathic -helix (5). This
might result in a less tight interaction with membranes, and
dissociation of NS5A from the replication complex might be
facilitated. In support of this hypothesis are recent publications
that demonstrate that mutations within NS5A can be trans-
complemented, whereas trans-complementation for all other
nonstructural proteins failed (6, 7).
This flexibility might facilitate the multiple functions attrib-
uted to NS5A. NS5A has been described to influence many
different cellular pathways (8). However, direct interaction
with the viral RNA-dependent RNA polymerase (9) as well as
with RNA (10) support the fact that NS5A also plays an impor-
tant role in viral replication.
Considering the numerous functions ascribed to this single
protein, it is not surprising that post-translational events play a
crucial role for the regulation of functions of NS5A. It has been
demonstrated by several groups that NS5A is a target of differ-
ent cellular proteases (11, 12), and it is easy to imagine that
different cleavage products might exert different cellular func-
tions. However, the most studied post-translational modifica-
tion of NS5A identified to date is phosphorylation. NS5A is
expressed as a basally phosphorylated (p56) and a hyperphos-
phorylated (p58) form (13), the production of the latter form
requires the presence of other HCV nonstructural proteins
(14–16). The requirements for NS5A hyperphosphorylation
are in remarkable agreement with two other previous observa-
tions as follows: trans-complementation could be obtained only
when NS5A was expressed in the context of an intact polypro-
tein coding fromNS3 to NS5A (6), and wild type NS5A exerted
a trans-dominant negative effect on adapted subgenomic repli-
cons only when expressed in the same context (17). Thus it
seems that the presence of the NS3, NS4A, and NS4B proteins
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are required for the production of a correctly folded, functional
NS5A protein. Whether NS5A hyperphosphorylation is the
cause or the consequence of correct folding in this context is
still to be established.
Besides the presence of other nonstructural proteins, NS5A
hyperphosphorylation requires the presence of three serine res-
idues (18) that are situated in a region between the first and the
second N-terminal domains of NS5A (19). Even though the
functional relevance of the different phosphorylated forms is
still unknown, it has becomemore andmore evident that a tight
regulation of NS5A phosphorylation is important for the out-
come of HCVRNA replication. The Con1wild type sequence is
able to replicate in cells only after acquisition of adaptivemuta-
tions, which in most cases reduce NS5A hyperphosphorylation
(20), or after reduction of hyperphosphorylated NS5A upon
incubation with NS5A hyperphosphorylation-specific kinase
inhibitors (21). In this case, the alteration of NS5A phosphoryl-
ation increases replication efficiency. There are, however, other
examples that indicate that alterations of a functional ratio
between NS5A-p56 and p58 negatively influence the outcome
of productive replication/infection. An actively replicating
HCV subgenome expressing a reduced level of NS5A-p58 is
completely inhibited if hyperphosphorylation is further
decreased either by introduction of a second adaptivemutation
(22) or by the addition of the NS5A hyperphosphorylation
inhibitors (21). In addition, introduction of a mutation that
reduces NS5A hyperphosphorylation into an infective clone
abrogates infection in the chimpanzee model (23). The latter
example, in particular, underlines the importance of NS5A-
p58 for replication/infection and points to the fact that the
cellular kinase responsible for NS5A hyperphosphorylation
might be a good alternative antiviral target besides the viral
enzymatic targets.
We aimed to identify this/these cellular kinase(s) using the
specific NS5A hyperphosphorylation inhibitors (NS5A-p58-i).
Upon screening of a panel of cellular kinases in vitro, we iden-
tified the family of casein kinase I (CKI) as a target of the com-
pounds, and using genetic tools we confirmed that the -iso-
form of CKI is important for the formation of NS5A-p58 (24).
Although this strategy helpedus to identifyCKI-, it has several
shortcomings because only a small subset of the cellular kinases
could be tested (60 out of500). Because of this limitation, we
cannot exclude the possibility that other cellular kinases not
present in the previous screen are a target of the NS5A hyper-
phosphorylation inhibitors and might participate on the same
pathway finally resulting in NS5A hyperphosphorylation. We
therefore adopted an alternative methodology, the inhibitor
affinity chromatography, to confirm CKI- as a target of the
compounds in a more physiological context in the presence of
ATP-binding proteins and competing cellular kinases and to
eventually identify additional kinases that might contribute to
NS5A hyperphosphorylation.
EXPERIMENTAL PROCEDURES
Antibodies, Plasmids, Enzymes, and Peptides—The antibod-
ies against CKI-, CKI-, CKI-, and JNK2 were purchased
from Santa Cruz Biotechnology and against p38 MAPK, RSK,
and PKA from Cell Signaling Technology. The NS5A-specific
antibodies have been described previously (21). All NS5A pep-
tides were synthesized by Bio-Synthesis Inc. CKI- and its sub-
strate peptide were purchased from New England Biolabs.
CKII, p38 MAPK, PKA, JNK1, JNK2, RSK2, and their respec-
tive substrates were obtained from Upstate. The plasmids
pcD-BLA-wt and pET26Ub-His-32 have been described
previously (21, 25). Plasmid pET14-R30-SR-K4 contains the
coding region of Con1-NS5A with the following modifica-
tions. The first 29 amino acids were deleted, and the NS5A
coding region starts with Arg-30. Ser-232 was mutated to
arginine (amino acid of the HCV polyprotein S2204R), and
four lysine residues were added to the C terminus to increase
solubility of the protein. The DNA plasmid pHCVNeo-SR is
identical to pHCVNeo17.wt, as described previously (26), but
contains themutation S2204R inNS5A. Plasmid pBAC-FLAG-
CKI- contains the CKI- coding region with an N-terminal
FLAG tag. The coding region of CKI- with the N-terminal
FLAG tag was taken from plasmid pCD-FLAG-CKI-, as
described previously (24), and cloned into the BamHI/NotI
cloning sites of pBAC-1 (Novagen). All modifications were per-
formed using standard recombinant DNA technology. Com-
pounds were synthesized as described previously (27).
Immobilization of H479 and A852-m—2 ml of drained epoxy-
activated Sepharose 6B (GE Healthcare) were equilibrated with
coupling buffer (50% dimethylformamide, 0.1 M Na2CO3), and
4 ml of 10 mM H479 or 5 mM of A852-m, dissolved in coupling
buffer, were incubated overnight at 37 °C in the dark with the
resin. After the incubation the resin was washed with coupling
buffer, and the remaining reactive groupswere blockedwith 1M
ethanolamine in coupling buffer for 5 h at 37 °C. Subsequent
washing steps were performed according to themanufacturer’s
instructions. To generate the control matrix, epoxy-activated
Sepharose 6B was directly reacted with 1 M ethanolamine in
coupling buffer and equally treated as described above. The
matrices were stored at 4 °C in the dark.
Extract Preparation and Inhibitor Affinity Chromatog-
raphy—10A-IFN cells (26) were lysed in Triton X-100 lysis
buffer (TL buffer) containing 50 mM HEPES, pH 7.5, 500 mM
NaCl, 0.5% Triton X-100, 1 mM EDTA, 10 mM EGTA, 10%
glycerol plus additives (10 mM sodium fluoride, 1 mM
orthovanadate, 1 mM dithiothreitol, protease inhibitors mix-
tureComplete (RocheApplied Science)). For protein binding in
batch, lysates were pre-cleared by centrifugation and equili-
brated to 1 M NaCl. Cell lysate (2 mg of total protein) was incu-
bated with 100 l of drained inhibitor-matrix for 2 h at 4 °C
with or without 2 mM of compound as indicated in the figure
legends. Unbound proteins were separated by centrifugation,
and resin was washed extensively first with TL buffer, 1 M NaCl
and then with TL buffer, 20 mM NaCl. Bound proteins were
directly denatured by addition of 1 volume of 2Laemmli sam-
ple buffer. Proteins were separated by SDS-PAGE, transferred
to nitrocellulose membrane, and immunoblotted with the cor-
responding antibodies. Secondary antibodies conjugated with
horseradish peroxidase were used, and enzymatic reactions
were developed using the ECL system (GE Healthcare). For
preparative binding experiments, protein extract was prepared
from 9 107 10A-IFN cells as described above, equilibrated to
1MNaCl, and loaded directly onto an inhibitor-matrix contain-
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ing chromatographic column. After binding, the column was
washed with 30 volumes of TL buffer, 1 MNaCl and 30 volumes
of TL buffer, 20mMNaCl. Bound proteinswere first elutedwith
3 volumes TL buffer, 20 mMNaCl containing 100 mMMg-ATP
and subsequently with 3 volumes of TL buffer, 20 mM NaCl
containing 100 mM Mg-ATP plus 1 mM compound.
Mass Spectrometry—Eluted proteins (400 l) were concen-
tratedwith the clean-up kit (GEHealthcare), separated by SDS-
PAGE and visualized by silver staining. The bands of interest
were excised and digested with trypsin for mass spectrometry-
based protein identification. Briefly, the gel pieces were incu-
bated with 20 l of 12.5 ng/l trypsin sequencing grade (Pro-
mega, Madison, WI) in 50 mM NH4HCO3 for 45 min at 4 °C.
Trypsin was then replaced with 50 mM NH4HCO3, and the gel
pieces were left overnight at 37 °C. Tryptic peptides were
extracted from the gel pieces by incubation in 50 l of 20%
formic acid in water (15 min) and pooled together with the
supernatants. The tryptic peptides were dried down in a Speed-
Vac concentrator, resuspended in 0.5% acetic acid, and ana-
lyzed by liquid chromatography coupled to electrospray ion
trap tandem mass spectrometry or subjected to ZipTip -C18
(Millipore) desalting prior to matrix-assisted laser desorp-
tion/ionization time of flight mass spectrometry. For liquid
chromatography coupled to electrospray ion trap tandem
mass spectrometry experiments, an LCQ Deca XP-Plus mass
spectrometer (Thermo Electron, San Jose´, CA) equipped with
an in-house built micro-electrospray source connected to an
in-house packed C18 column (100 mm 0.10 mm, 5 m par-
ticle size) was used. Protein identification from collision-in-
duced dissociation data was done with TurboSequest software
provided by the manufacturer.
Formatrix-assisted laser desorption/ionization time of flight
mass spectrometry experiments, a Voyager-STR mass spec-
trometer (Applied Biosystems, Foster City, CA) was used,
which operated in positive reflectron mode using -cyano-4-
hydroxycinnamic acid (10 mg/ml in water/acetonitrile 3:7, 1%
trifluoroacetic acid) as matrix. Internal calibration was used.
MASCOT software package (Matrix Science, London, UK) was
used to identify proteins from independent nonredundant
sequence data bases.
Protein Expression andMetabolic Labeling of Proteins—Pro-
tein expression using the vaccinia T7 infection/transfection
system was performed as described (14). 3.5  105 10A-IFN
cells/35-mm diameter dish were plated the day before the
experiment. 2 g of total plasmid DNA was transfected using
FuGENE 6 (Roche Applied Science) as transfection reagent.
Metabolic labeling and immunoprecipitation were performed
as described. Inhibitors were added during the starvation reac-
tion and were present during metabolic labeling of the cells.
RNA Interference—siRNAs were transfected by electropora-
tion (21). Briefly, 10 M siRNA were electroporated in 1 106
10A-IFN cells in a volume of 0.1 ml. After electroporation,
4.5 105 cells were plated in a 35-mm diameter dish and incu-
bated for 2 days. After 2 days, HCV proteins were expressed
with the vaccinia T7 infection/transfection system as described
above. The siRNA sequences are described as follows: CIT
sense, 5-accuuuaucuggucauggatt-3; GAK sense, 5-gacaagau-
gcgggacuuuatt-3; RIPK2 sense, 5-ggaaucauguggauccucutt-3;
PKA sense, 5-cagaguuccuugcaucuaauutt-3; RSK2 sense, 5-
cucaugacuccuuguuacauutt-3; CaMKII sense, 5-cacuacuugg-
uguuugauuuutt-3. siRNAs for CKI-, CKI-, and CKI- were
described previously (24).
Quantitative PCRwas performed as described (21) using 100
ng of RNA. Primers and probes are described as follows: CIT
forward, 5-cagggttgggaagtccttagg-3, CIT reverse, 5-gttctgta-
ccagttgccaggaat-3, and CIT probe, 5-ctgcggaccctcctattaga-
gtacg-3; GAK forward, 5-cccgaaggaacagctgattc-3, GAK
reverse, 5-cgcccgaaacaccaaataaa-3, and GAK probe, 5-cctcc-
cgcaattgtcacgtctgtg-3; RIPK2 forward, 5-acgtctgcagcctggtat-
agc-3, RIPK2 reverse, 5-ggcaggcttctgtcatttgg-3, and RIPK2
probe, 5-tggatccagagcaaaagggaagacattgt-3; PKA forward, 5-
agccggagaatctgctcattg-3, PKA reverse 5-cacgcgcttggcgaaac-
3, and PKA probe, 5-ccagcagggctacattcaggtgacagactt-3;
RSK2 forward, 5-cttgtgtgtgtgaaaagtcagttatga-3, RSK2 reverse,
5-gtacactgcatgtgaaatgtggaa-3, and RSK2 probe, 5-tctggagag-
aagctgtggtgtgtatgctgt-3; and CaMKII forward, 5-gcggatcgtt-
tcgcaact-3, CaMKII reverse, 5-gccgggaaatggaaaaaca-3, and
CaMKII probe, 5-ttgccactcgtcccgtgcctg-3. All probes con-
tain the 6-carboxyfluorescein dye at the 5-end and the 6-car-
boxy-N,N,N,N-tetramethylrhodamineTAMRA quencher at
its 3-end. As endogenous standard we used the glyceralde-
hyde-3-phosphate dehydrogenase probe, containing the VIC
dye at its 5-end (Applied Biosystems). Reactions are conducted
in three stages under the following conditions: stage 1, 30min at
48 °C; stage 2, 10min at 95 °C; stage 3, 15 s at 95 °C and 1min at
60 °C, 40 cycles. The total volume of the reaction is 50 l.
In Vitro Kinase Assays—All protein kinase activities were lin-
ear with respect to time in each incubation. If not mentioned
differently, all reactions were performed in the presence of 125
M cold ATP, 0.2 l of [-33P]ATP (2 Ci/point), and 18 mM
MgCl2 in reaction buffer (10 mM MOPS, pH 7.2, 12.5 mM
-glycerol phosphate, 2.5 mM EDTA, 0.5 mM sodium
orthovanadate, and 0.5 mM dithiothreitol) in a final volume of
50 l for 30 min at room temperature. For the calculation of
IC50 values, compounds were added in a range between 0.1 nM
and 1 mM resulting in a final Me2SO concentration of 5%. The
reactions were initiated by the addition of ATP and stopped by
the addition of 10 l of 3% phosphoric acid, and 20 l of the
reaction were spotted onto P30 Filtermat (Wallac). The filter
was washed three times for 5 min with 75 mM phosphoric acid
and once with methanol. Radioactivity was counted in 5 ml of
Ready Protein scintillation mixture (Beckman Coulter). CKI-,
CKI- (4 l of purified fraction, see below), and CKII were
tested as described previously (24). PKA (5 ng) was assayed in
the presence of the PKC/CaMK inhibitor mixture (Upstate)
using 30 M peptide substrate, and RSK2 (10 ng) was tested
using 100 M peptide substrate. Activity of p38 MAPK (80 ng)
was assayed using myelin basic protein (40 g) as substrate.
Activity of JNK1 and JNK2 (30 ng) was assayed in 50 mM
Tris/HCl, pH 7.5, 0.1 mM EGTA, and 0.1% 2-mercaptoetha-
nol using 3 M ATF2 as substrate peptide. For in vitro phos-
phorylation of NS5A, 2M purified NS5A (25) was incubated
in the same conditions as described above in a final volume
of 60 l with 12 l of purified CKI- (see below), 120 ng of
CKI-, 250 ng of CKII, or 500 ng of PKA, respectively, for 1 h
at room temperature.
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Expression and Purification of NS5A andCKI-—Expression
and purification of NS5A from plasmid pET26Ub-His-32 was
performed as described (25). Expression of NS5A from plasmid
pET14-R30-SR-K4 was performed in BL21-codon plus (Strat-
agene). Cells were grown in LB medium to a density of 0.8 and
induced with 0.4 mM isopropyl 1-thio--D-galactopyranoside
at 18 °C for 16 h. Purification was performed as described (28)
with the following modifications. All buffers contained 0.3%
n-octyl--D-glucopyranoside instead of Triton X-100. Lysis
buffer contained 25mMHepes/HCl (pH7.5), 50% glycerol, 0.3%
n-octyl--D-glucopyranoside, 500 mM NaCl, 2 mM dithiothrei-
tol, 1mMEDTA, protease inhibitors (Complete, Roche Applied
Science). Gel filtration was performed in 200 mM NaCl. Active
fractions were loaded onto aMono S column after gel filtration
for concentration.
Isolation of recombinant baculovirus (Bacmid) expressing
FLAG-CKI- was performed as described by manufacturer
(Bac-to-Bac baculovirus expression system; Invitrogen). Pro-
tein expression was performed as described previously for
NS5A (28) with the exception that infection was performed at
room temperature. Cell extract was prepared in lysis buffer
containing 25 mM HEPES pH 7.5, 300 mM NaCl, 1% Triton
X-100, 40% glycerol, 10mMNaF, 1mMEDTA, 2mMdithiothre-
itol, protease inhibitors (Complete, Roche Applied Science).
The cell extract was clarified by centrifugation and glycerol
concentration was diluted to 20% before incubation with anti-
FLAG-agarose (Sigma) for 4 h at 4 °C. The anti-FLAG-agarose
was washed extensively with lysis buffer without glycerol. Elu-
tion of the FLAG-tagged proteins was performed with 3 vol-
umes of elution buffer (50mMHEPES pH 7.5, 100mMNaCl, 5%
glycerol, 0.05% Triton X-100) containing 100 g/ml of FLAG-
peptide (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys; Sigma) for 1 h at
room temperature. Eluted proteins were stored at20 °C.
RESULTS
Design of Inhibitor Affinity Chromatography—We have pre-
viously identified specific inhibitors of the NS5A hyperphos-
phorylation (21). The chemical structure of two of these com-
pounds, H479 and A852, is shown in Fig. 1. The compounds
belong to the class of 2, 4, 5-trisubstituted imidazoles, which are
known to bind to the active site of kinases and are competitive
with ATP. To purify the kinases targeted by these compounds,
we generated affinity resins by immobilizing the kinase inhibi-
tors to a solid matrix. The choice of the inhibitor orientation
with respect to thematrix is important to ensure a correct inter-
action of the target protein with the inhibitor. In general, a
co-crystal structure of the inhibitorwith the target protein indi-
cates the area of the inhibitor that can be attached to thematrix.
In our case this information is not available, and we had to
utilize alternative sources of information. Godl et al. (29) have
successfully identified cellular targets of the p38 kinase inhibi-
tor SB203580. This inhibitor is structurally related to the
NS5A-p58-i (Fig. 1), which also potently inhibits p38 (24). Con-
sequently, we attached compoundH479 andA852 to an epoxy-
activated Sepharosematrix at the position corresponding to the
sulfoxide substituent of SB203580. Whereas compound H479
contained a reactive amine at the desired position, compound
A852 had to be modified such that a reactive amine was intro-
duced into this position (Fig. 1, compound A852-m). We tested
the activity of this modified compound (A852-m) in an NS5A
hyperphosphorylation assay and observed a 2–3-fold reduction
of activity after introduction of this modification (data not
shown). The affinity matrix was prepared as described under
“Experimental Procedures,” and total cell lysate prepared from
10A-IFN cells was incubated with this matrix at high salt con-
centrations to reduce nonspecific protein binding. The choice
of elution conditions enabled us to distinguish between those
proteins that bind to the compound with low affinity from
those with high affinity. Although low affinity binding proteins
or ATP-binding proteins (theNS5A-p58-i are competitive with
ATP) might be eluted in the presence of ATP alone, high affin-
ity binding proteins require ATP together with the specific
compound for efficient elution.
A Distinct but Overlapping Kinase Profile Is Obtained with
Two NS5A Hyperphosphorylation Inhibitors—For the identifi-
cation of cellular targets of theNS5A-p58-i, cellular lysates pre-
pared from 10A-IFN cells were loaded onto the inhibitor affin-
ity columns. After extensive washing, proteins were first eluted
with 100 mM ATP and subsequently with 100 mM ATP plus 1
mM specific compound. Eluted proteins were separated by
standard SDS-PAGE and analyzed by mass -spectrometry (Fig.
2 and Table 1). The elution profiles in the presence of 100 mM
ATP with or without 1 mM compound clearly differ indicating
that this pre-elution step might have separated low affinity
binding or ATP-binding proteins from those proteins with
higher affinity for the compounds. Interestingly, most of the
bound proteins were kinases belonging to five different kinase
families. In addition to this enzyme class, non-kinase targets
such as tubulin, actin, prohibitin, glutamine synthetase, and
aldehyde dehydrogenase were also found to bind the affinity
matrix. These proteins bind nucleotides such as ATP orNADH
and might associate with the affinity matrix because of their
high abundance within the cell. In fact most of these proteins
eluted in the presence of ATP alone indicating that binding is
because of their affinity for nucleotides rather than for the spe-
cific compounds.
The in vitro screening of a selected panel of kinases has
shown that only four enzymes, CKI-, CKI-, CKI-, and p38
MAPK, were efficiently inhibited by three NS5A-p58-i (24). In
FIGURE 1. Chemical structure of the kinase inhibitors used in this work.
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this study, we offered a complexmixture of cellular kinases and
nucleotide-binding proteins present in crude cell extracts.
Despite the high complexity of proteins offered to the affinity
matrix, only CKI-, CKI-, CKI-, and p38 MAPK bound to
both NS5A-p58 inhibitor columns with high affinity and
required the presence of compound for efficient elution, thus
confirming the previous results. In addition to this common
subset of protein kinases, there are also protein targets binding
specifically either to compound H479 or to compound A852.
For the H479-matrix, RIPK2 was the only high affinity binding
kinase present in the ATP/H479 fraction. Even though we also
identified RSK1/2, it seems that this kinase interacts with the
H479-matrix with lower affinity because most of the RSK1/2
eluted in theATP fraction indicating that the amount of protein
found in theATP/compound fraction reflects incomplete elu-
tion from the previous elution step. In the ATP fraction of
the H479-matrix, we identified, in addition to RSK1/2, also
the kinases JNK1, JNK2, and CaMKII. For the A852-m-
matrix, the high affinity binding kinases present in the ATP/
A852 fraction are, in addition to CKI and p38 MAPK, PKA
and JNK2. CIT and GAK are present in the low and high
affinity fractions, indicating a lower affinity of these kinases
for the compounds. In addition to CIT and GAK, we also
identified GSK3, JNK1, and a small amount of PKA in the
ATP fraction of the A852-m resin.
In Vitro Analysis of the Target Proteins—To confirm the
results obtained by mass spectrometry, we repeated the exper-
iment by batch incubation of the affinity resins with the cellular
extracts and tested the identity of bound kinases by Western
blot analysis. Different affinities of the cellular kinases for the
two NS5A hyperphosphorylation inhibitors H479 and A852
were proven by competition of the compounds in solution dur-
ing the binding reaction. The results are shown in Fig. 3. This
type of assay measures binding of proteins to the affinity resin,
which depends on the intrinsic affinity of the protein for the
compound, on the concentration of the compounds linked to
the matrix, and on the abundance of the protein in the cellular
extract. In addition, we measured the IC50 values of both com-
pounds for some kinases to obtain more quantitative informa-
tion (Table 2). None of the kinases tested bound to the control
resin (Fig. 3, lanes 2 and 3). CKI-, CKI-, CKI-, and p38, all
kinases binding to both affinity resins with high affinity,
behaved similarly and were competed completely in the pres-
ence of either H479 or A852 (Fig. 3, compare lane 5 with lanes
FIGURE 2. Inhibitor affinity chromatography with the NS5A hyperphos-
phorylation inhibitors. Cellular proteins were passed through a column
containing covalently bound H479 (left) or A852-m (right), and proteins were
eluted either with ATP or with ATP plus compound. After elution, proteins
were concentrated, separated by 10% SDS-PAGE, and visualized by silver
staining. Identified proteins are listed in Table 1.
FIGURE 3. Confirmation of binding and different compound affinities of
identified kinases by immunoblot analysis. Cellular proteins were bound
in batch either to the control matrix (c) or to the affinity-matrix H479 or
A852-m as indicated in the affinity-matrix lane. The presence of competitive
compound during the binding reaction is indicated in the competitor lane.
Unbound (u) and bound (b) proteins were separated by SDS-PAGE, trans-
ferred to nitrocellulose, and detected with specific antibodies as indicated in
the figure. I, input extract.
TABLE 1
Identification of proteins isolated by inhibitor affinity
chromatography bymass spectrometry analysis
No. of
proteins Protein name
Swiss-Prot
accession no.
1 RSK1/2 Q15418/P51812
2 Aldehyde dehydrogenase P30837
3 JNK2 P45984
4 CaMKII Q13557
5 JNK1 P45983
6 Prohibitin P35232
7 RIPK2 (receptor-interacting serine/
threonine protein kinase 2)
O43353
8 CKI-/CKI- P48730/P49674
9 Glutamine synthetase P15104
10 p38-, -MAPK Q16539/Q15759
11 CKI- P48729
12 CIT (citron Rho-interacting kinase) O14578
13 GAK (cyclin G-associated kinase) O14976
14 GSK3 (glycogen synthase kinase-3) P49841
15 Actin P60709
16 Tubulin P68366
17 PKA C- P17612
TABLE 2
Calculation of IC50 values of the NS5A hyperphosphorylation
inhibitors H479 and A852 for different cellular kinases in vitro
H479
IC50 (M)
A852
IC50 (M)
p38 MAPK 0.028 0.024
CKI- 1.4 0.4
CKI- 1.1 1.3
PKA 260 2
JNK1 385 175
JNK2 404 166
RSK2 76 39
CKII 100 100
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7 and 9 and lane 11 with lanes 13 and 15). This result was
expected because the concentrations used for competition (2
mM) were more than 1000-fold the IC50 value of these kinases
(see Table 2). Binding and competition of the other kinases
reflect the binding affinities already observed in Fig. 2 and can
be explained with the IC50 value shown in Table 2. PKA binds
with high affinity to immobilized A852-m (Fig. 3, lane 11),
whereas no binding is detected to theH479 resin (Fig. 3, lane 5).
Although A852 efficiently competes in binding (2000 IC50,
Fig. 3, lanes 14 and 15), 2mMH479 (7 IC50) is not sufficient to
complete competition of PKA binding (lanes 12 and 13). In
contrast, RSKbinds to theH479 resin (Fig. 3, lane 5) and not the
A852-m resin (lane 11). Binding affinity of RSK for compound
H479, however, is lower than binding affinity of PKA for com-
pound A852, because ATP is sufficient for elution of RSK (Fig.
2). In addition, 2 mM of either A852 or H479 in solution is
sufficient to compete for RSK binding to the H479 resin (Fig. 3,
lanes 6–9). The IC50 values for both compounds are similar,
andwe assume that the reduction in potency upon introduction
of the modification into A852 might explain why RSK does not
bind to the A852-m resin. JNK2 represents a third example.
JNK2 binds to both affinity resins (Fig. 3, lanes 5 and 11). How-
ever it binds with low affinity to immobilized H479 (elutes with
ATP alone) and with higher affinity to immobilized A852-m
(ATP/compound fraction) (Fig. 2). The IC50 value for both
compounds is in the highmicromolar range, and probably high
abundance of the kinase within the cell contributes to the bind-
ing reaction. Nevertheless, the higher affinity of the kinase for
compoundA852 is confirmed during the competition reaction,
where H479 only partially competes for binding to the A852-m
resin (Fig. 3, lanes 12 and 13), whereas A852 is able to compete
completely (lanes 14 and 15).
Taking all this information together, we have confirmed the
binding of some of the kinases byWestern blot analysis, and we
have shown that affinity of binding shown in Fig. 2 generally
correlates with the IC50 of the compounds for the kinases.
RNA Interference Experiments Confirm CKI- as the Unique
Target Kinase Important for NS5A Hyperphosphorylation—
The inhibitor affinity chromatography has revealed additional
cellular kinases that could be potential targets for the NS5A
hyperphosphorylation inhibitors. Themost effectiveway to test
whether these kinases influence NS5A hyperphosphorylation
turned out to be RNA interference of the single kinases. Kinases
were silenced for 48 h, and the HCV polyprotein was expressed
in this cellular background using the vaccinia T7 infection/
transfection system. Phosphorylation ofNS5A after silencing of
the indicated kinases is shown in Fig. 4. The typical 1:1 ratio of
NS5A-p56 and p58 remains constant in all cases except after
silencing of CKI-, where a clear decrease of p58 can be
observed. Silencing efficiency varied between 9% in the case of
PKA mRNA and CKI- mRNA and 35% for CaMK mRNA as
calculated by quantitative PCR. We cannot exclude the possi-
bility that residual activities of the kinases after silencing might
still be sufficient for complete NS5A hyperphosphorylation;
however, under this experimental setting the only kinase that
changes phosphorylation pattern of NS5A is CKI-.
Hyperphosphorylation of NS5A Occurs upon Incubation with
CKI- in Vitro—The data shown above demonstrate that
CKI- is the only kinase that is a target of both NS5A hyper-
phosphorylation inhibitors and that is required for NS5A
hyperphosphorylation. These data, however, do not indicate
whether NS5A is a direct substrate of CKI- or whether CKI-
is an upstream kinase of a pathway finally resulting in NS5A
hyperphosphorylation. We performed an in vitro kinase assay,
in which we incubated several kinases withNS5A purified from
Escherichia coli as a substrate (Fig. 5). BesidesCKI- andCKI-,
we used CKII and PKA as control kinases, both kinases which
have been reported to phosphorylate NS5A in vitro (30, 31).
The most interesting result of this experiment is the appear-
ance of a slower migrating band (p58*), which resembles the
hyperphosphorylated form ofNS5A-p58 produced in cells (Fig.
5, B andC). p58* appeared with time upon incubation with CKI
but not with CKII or PKA. Doubling the enzyme concentration
of CKII did not result in the production of p58* (data not
shown). The reaction is slowed down in the presence of com-
pound H479 with the consequence that the phosphorylation
state of NS5A after 4 h of incubation in the presence of com-
pound is comparable with a 20-min incubation without com-
pound. Mutations at serine residue Ser-2204 are frequently
found as adaptive mutations and significantly decrease NS5A
hyperphosphorylation (20). We have introduced the S2204R
mutation in NS5A, and the effect on NS5A hyperphosphoryla-
tion is clearly visiblewhen expressed from theHCVpolyprotein
in cells (see Fig. 5C, lane 4). Interestingly, the same effect could
also be observed in the in vitro kinase reaction, in which only
NS5A is present (Fig. 5C, lane 2). This observation supports the
idea that the in vitro reactionmight reproduce NS5A phospho-
rylation/hyperphosphorylation observed so far only in cells.
The difference in migration of NS5A expressed in E. coli is
probably because of theN-terminal deletion of the amphipathic
helix, which was removed to facilitate expression and purifica-
tion (Fig. 5A). As this deletion is the only significant difference
betweenNS5A expressed in cells andNS5A expressed inE. coli,
we tested whether this deletion enables NS5A hyperphospho-
rylation in cells evenwhen expressed as a single protein and not
in the context of the HCV polyprotein. However, as demon-
strated in Fig. 5C, lanes 5–7, hyperphosphorylation of NS5A in
FIGURE 4. CKI- is the only target kinase important for NS5A hyperphos-
phorylation. The indicated kinases were silenced in 10A-IFN cells as
described under “Experimental Procedures.” 48 h after siRNA transfection, 2
g of pcD-Bla-wt were transfected, and proteins were expressed using the
vaccinia T7 infection/transfection system. Proteins were labeled, and NS5A
was immunoprecipitated as described. Shown is an autoradiogram. Effi-
ciency of silencing of the different kinases is shown at bottombyquantitative
reverse transcription-PCR (QP). Numbers indicate mRNA expression level of
the different kinases with respect tomock-transfected cells (100%). The posi-
tion of NS5A-p56 and NS5A-p58 and migration of protein standard with 66
kDa, respectively, are indicated on the left.
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cells requires the presence of the HCV nonstructural proteins,
independent of the N-terminal amphipathic helix.
Ser-2204 Is a Preferred Phosphorylation Site of CKI-—The
experiment shown above clearly demonstrates that NS5A is
directly phosphorylated by CKI-.
Knowing the importance of the ser-
ine residues Ser-2197, Ser-2201, and
Ser-2204 for NS5A hyperphospho-
rylation, we investigated whether
these serine residues may be phos-
phorylated by CKI-. CKI prefers
substrates that have been previ-
ously phosphorylated by other
kinases within the consensus
sequence (S/T)(P)X1–2(S/T) (32).
Interestingly, the region of hyper-
phosphorylation is a hot spot for
CKI recognition, containing many
potential consensus sequences (Fig.
6A). We designed five peptides
spanning the region from residue
Gly-2193 to Lys-2212, either
unphosphorylated (Pep 1) or phos-
phorylated at a single defined serine
residue. These peptides were
offered as substrates to CKI in an in
vitro kinase assay, and the results
are shown in Fig. 6B. The activity of
different isoforms of CKI on protein
substrates depends on the intact
tertiary structure of the substrates,
whereas the specific activity on pep-
tide substrates is virtually identical
(33). We therefore performed the
experiment using CKI- available
from a commercial source. The
most efficiently phosphorylated
substrate peptide is Pep 4. Phospho-
rylation of peptide 4 depends on the
presence of phosphoserine 2201
(compare peptide 1 with 4). Com-
parison of the sequence of peptide 4
with the CKI consensus sequence
suggests that Ser-2204 is phospho-
rylated by CKI-. This assumption
was confirmed by Pep 6. In this pep-
tide Ser-2204 was substituted by
alanine, resulting in complete aboli-
tion of CKI- activity. In Pep 7 we
exchanged Ser-2201 with glutamic
acid to test whether phosphoryla-
tion of Ser-2201 is important or
whether the presence of a negative
charge is sufficient for phosphoryla-
tion of Ser-2204. As shown in Fig.
6B, the S2201E substitution com-
pletely abolished the activity of
CKI-, indicating that phosphoryla-
tion of Ser-2201 is required. Similar experiments with recom-
binant CKII showed no activity on these peptides (data not
shown). To confirm that the activity of CKI- on peptides 1–5
is comparable with the activity of CKI-, the experiment was
FIGURE 5.NS5A is hyperphosphorylated in vitro by casein kinase 1. A, schematic presentation of the NS5A
sequence used for expression in Huh7 cells or in E. coli.-,N-terminal deletion of amphipathic helix. Purified
proteinsmay contain a histidine tag at the N terminus (6xHis) or a lysine tail at the C terminus (K4) as described
under “Experimental Procedures.” B, production of NS5A-p58* in vitro by CKI. Purified NS5A expressed in E. coli
was incubatedwith CKI-, CKI-, CKII, or PKA in the presence or absence of 10MH479 for 0, 20, 80, or 240min
at room temperature with [-33P]ATP as described under “Experimental Procedures.” Proteins were separated
by SDS-PAGE and shown is the autoradiogram. The position of in vitro labeled NS5A is indicated as p56* and
p58* on the left. C, in vitroNS5A phosphorylationmimics phosphorylation in cells however, it does not require
the presence of HCV nonstructural proteins. Purified NS5Awas phosphorylated either in vitro by CKI- (lanes 1
and 2) or was expressed in Huh7 cells either alone (5A, lanes 6 and 7) or in the context of the HCV polyprotein
(3–5B, lanes 3–5) using the vaccinia T7 infection/transfection system.NS5Awas expressed either from theCon1
wild type sequence (wt, lanes 3, 5, and 6), from an S2204R-mutated sequence (SR, lane 4), from a sequence
containing an N-terminal deletion of the amphipathic helix (-, lanes 1 and 7) or containing both the N-ter-
minal deletion and the S2204Rmutation (lane 2). Proteinswere labeled, andNS5Awas immunoprecipitated as
described. Shown is an autoradiogram. Migration of NS5A-p56, p58, p56*, and p58* is indicated.
FIGURE 6. Efficient phosphorylation of an NS5A peptide requires pre-phosphorylation of Ser-2201.
Seven different peptides spanning the region of the NS5A hyperphosphorylation siteswere incubatedwithCKI
as described under “Experimental Procedures.” A, schematic presentation of the seven peptides. Phosphorylated
serine residuesare shown in red.Putative substrate serine residuesofCKIwithin theconsensus sequenceare shown
in blue. The S2204Amutation is shown in green, and the S2201E mutation is shown in pink. B, in vitro activity of
CKI- on NS5A peptides at increasing peptide concentrations. C, in vitro phosphorylation of peptides 1–5 by
CKI- at a single peptide concentration. 33P incorporated in the peptides is shown as disintegrations/min on
the y axis at various concentrations of the substrate peptides (x axis).
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repeated at a single peptide concentration with the CKI- iso-
form. Fig. 6C shows that peptide preferences of the different
CKI isoforms are indeed comparable.
DISCUSSION
It is generally accepted that NS5A phosphorylation plays a
key role in the regulation of HCV replication. Several kinases
have been implicated in NS5A phosphorylation mainly using
biochemical experiments (30, 31, 34). We have demonstrated
for the first time that CKI- is directly involved inNS5A hyper-
phosphorylation in cells (24). CKI- is a target of the NS5A-
specific hyperphosphorylation inhibitors, which were used in
an in vitro screen of a panel of 60 kinases. In this study, we
adopted an alternativemethodology, the inhibitor affinity chro-
matography, to confirm CKI- as a target of the NS5A-p58-i in
a more complex context of other competing cellular kinases
and ATP-binding proteins. In addition, other targets not pres-
ent in the previous screening were identified and evaluated for
their effect on NS5A phosphorylation.
Most of the proteins binding to the affinity matrix were
kinases, even though non-kinase ligands could be identified.
Binding of these non-kinase targets like tubulin, actin, prohib-
itin and aldehyde dehydrogenase most likely can be explained
by their cellular abundance and their general affinity for nucle-
otides. p38 MAPK and CKI, those kinases that we have shown
previously to be inhibited in vitro by all three NS5A-p58-i, also
bind to both inhibitor-matrices with high affinity, thus con-
firming that their affinity is high enough to compete with all
other cellular kinases and nucleotide-binding proteins. Affini-
ties of binding of the different targets varied between the low
nanomolar range up to the high micromolar range. The fact
that protein kinases that were only moderately inhibited by the
compound(s) (IC50400M)were able to stably associate with
the affinity resin suggests that their isolation may result from
higher cellular abundance. High local concentration of com-
pound on the resin might also facilitate binding. In addition,
whereas calculation of the IC50 value is performed in the pres-
ence of 125 M ATP, intracellular ATP is diluted out during
extract preparation, and thus the binding reaction is performed
in the absence of competing ATP.
As a matter of fact, some of the identified kinases have
already been isolated using the inhibitors SB203580 or
pyrido[2,3-d]pyrimidine (29, 35). The authors concluded that
these two inhibitor classes have an overlapping set of cellular
protein kinase targets. The NS5A hyperphosphorylation inhib-
itors are structurally related to SB203580 (Fig. 1), and it is there-
fore not surprising that this set of kinases associates with the
NS5A kinase inhibitors as well. All kinases that were identified
in the high affinity fractions of the compounds were tested for
their effect on NS5A hyperphosphorylation using the method
of RNA interference.With the exception of CKI-, silencing of
none of the other kinases changed the NS5A phosphorylation
pattern. These results suggest that CKI-may be the only cel-
lular kinase present in Huh7 cells that is targeted by all NS5A
hyperphosphorylation inhibitors and is important for NS5A
hyperphosphorylation. It would be possible, however, that the
extent of phosphorylation of NS5A by kinase(s) could also be
differentially altered in HCV-infected host cells with respect to
that in uninfected host cells. Thus, additional kinases important
for NS5A phosphorylation might have been missed with our
approach.
Nevertheless, the fact that p38 and probably also RIPK2, CIT,
and GAK are efficiently inhibited by these inhibitors might
account for undesired off-target activities. PKA is the only
kinase tested in this work on which the two compounds A852
and H479 showed a clear difference in potency. At 8 M con-
centration, a concentration sufficient to inhibit NS5A hyper-
phosphorylation and activate replication of wild type Con1
RNA in cells (21), PKA is significantly inhibited by A852 (IC50 2
M) but not at all by H479 (IC50 270 M). It was shown previ-
ously that A852 activates replication of wild type Con1 HCV
RNA less efficiently than H479 (21), and this difference might
be explained by selective inhibition of PKA by A852. As a gen-
eral observation, one can state that A852 inhibits kinases with
lower IC50 values compared with H479 and competes more
efficiently in solution (Fig. 4). By comparing the structure of the
two compounds, it would be possible that the bulky trifluoro-
methyl group present inH479 hampers the interactionwith the
active site of most kinases, thus explaining this observation.
So far, biochemical experiments demonstrated that NS5A is
a substrate of several kinases. However, a form ofNS5Amigrat-
ing at a higher molecular weight in an SDS gel, as expected for
p58, was never observed (see CKII and PKA in Fig. 5). We
noticed here for the first time that E. coli-expressed NS5A pro-
duces a slowermigrating band upon incubation with CKI. Even
though we do not know whether the phosphorylated sites pro-
duced in vitro and in cells are the same, the similarity of the
migration pattern is striking. For this reasonwe refer to the two
NS5A protein bands as p56* and p58*. This result has two
important implications. (i) CKI- is sufficient for basal phos-
phorylation of NS5A to produce p56*, which is then converted
to p58* by the same kinase. No other kinase is required for the
production of both p56* and p58* in vitro. This obviously does
not exclude the possibility that in cells additional kinases might
be involved in NS5A phosphorylation or regulation of NS5A
phosphorylation. (ii) In contrast to what has been observed to
date, no other nonstructural protein is required for the produc-
tion of p58* in this in vitro experiment. It seems that protein
folding and localization within the cell seem to play a crucial
role for correct NS5A phosphorylation. NS5A has to be part of
the replication complex and is localized together with all other
HCV nonstructural proteins in the membranous structures
through theN-terminal amphipathic helix. It would be possible
that fixing the N terminus of NS5A to the membranes puts
constraints on protein folding, which requires the presence of
NS3/4A, NS4B, and maybe also viral RNA for correct folding.
On the other hand, removal of this constraint, i.e. attachment to
the membranes via the amphipathic helix, does not facilitate
NS5Ahyperphosphorylation (Fig. 5C). Thismight indicate that
localization of NS5A at the membranes is indeed important for
hyperphosphorylation. Interestingly, CKI- is found in differ-
ent membrane compartments, and its activity is differentially
regulated by components within these membranes (36).
Correct folding exposes those sites important for basal phos-
phorylation, which in turn are the basis for hyperphosphoryla-
tion. The in vitro experiments using theNS5Apeptides indicate
HCVNS5A Is a Direct Substrate of CKI-
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that Ser-2204 is a substrate residue for CKI-. The requirement
of pre-phosphorylated Ser-2201 hints to a hierarchical order of
phosphorylation. Even though Ser-2201 is not a substrate of
CKI- in the context of a peptide, one cannot exclude the pos-
sibility that Ser-2201 is phosphorylated byCKI- in the context
of a full-length protein. In fact, CKI is able to produce p58* in
vitro, which might require pre-phosphorylation of Ser-2201. In
the more natural context of a living cell, this pre-phosphoryla-
tion of Ser-2201might well be performed by a different cellular
kinase.
We have shown in this work that several different protein
kinases are targets of the NS5A hyperphosphorylation inhibi-
tors; however, only CKI- is important for NS5A hyperphos-
phorylation. The NS5A hyperphosphorylation inhibitors will
have to be optimized in order to efficiently inhibit CKI- but
also to be as inefficient as possible against the other cellular
targets. Using purifiedNS5Aproduced inE. coli plus CKI-, we
were able to reproduce NS5A phosphorylation/hyperphospho-
rylation in vitro, a pattern normally only observed in eukaryotic
cells in the context of the HCV polyprotein. This offers for the
first time a potent tool with which various phosphorylated
forms of NS5A can be dissected and investigated for their dif-
ferent functions in HCV RNA replication and infection.
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